Neesha C Dhani
Overview
Explore the profile of Neesha C Dhani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alqaisi H, Cohn D, Chern J, Duska L, Jewell A, Corr B, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836408
Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization...
2.
Madariaga A, Jivraj N, Soberanis Pina P, Somji F, Truong T, Melwani S, et al.
Int J Gynecol Cancer
. 2024 May;
34(10):1612-1618.
PMID: 38821545
Objectives: Implementation of an interprofessional program at Princess Margaret Cancer Centre, including nurse-led proactive calls to support patients with gynecologic cancers with malignant bowel obstruction, demonstrated improved outcomes compared with...
3.
Madariaga A, Bhat G, Wilson M, Li X, Cyriac S, Bowering V, et al.
Am J Obstet Gynecol
. 2024 Apr;
231(1):141.
PMID: 38679558
No abstract available.
4.
Madariaga A, Cole H, Pittman T, Grant R, Dhani N, Liu A, et al.
Gynecol Oncol
. 2024 Feb;
185:1-7.
PMID: 38342004
Objective: The primary objective is to assess factors associated with treatment related high grade (CTCAE grade ≥ 3) adverse event (AE) reporting among participants in gynecologic oncology clinical trials. Methods:...
5.
OBrien S, Ubhi T, Wolf L, Gandhi K, Lin S, Chaudary N, et al.
Cancer Res Commun
. 2023 Nov;
3(12):2596-2607.
PMID: 38032106
Significance: We have elucidated the synthetic lethal interactions between FBXW7 mutation and DNA damage response genes, and highlighted the potential of ATR inhibitors as targeted therapies for cancers harboring FBXW7...
6.
Jangra R, Dhani N
Clin Cancer Res
. 2023 Sep;
29(22):4521-4523.
PMID: 37698948
Mismatch repair (MMR) status alone is insufficient to guide the use of PD-(L)1 monotherapy in patients with endometrial cancer. Additional biomarkers, including tumor mutational burden and combined positive score, may...
7.
Lheureux S, Prokopec S, Oldfield L, Gonzalez-Ochoa E, Bruce J, Wong D, et al.
Clin Cancer Res
. 2023 Jun;
29(18):3706-3716.
PMID: 37327320
Purpose: To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high-grade serous ovarian cancer (HGSOC). Experimental Design: We used...
8.
Tinker A, Dhani N, Ghatage P, McLeod D, Samouelian V, Welch S, et al.
Ther Adv Med Oncol
. 2023 Mar;
15:17588359231157633.
PMID: 36950270
Background And Objectives: Endometrial cancer is a common malignancy and recurrences can be fatal. Although platinum-pretreated endometrial tumors are commonly treated with anthracyclines and taxanes, there is no current standard...
9.
Madariaga A, Garg S, Tchrakian N, Dhani N, Jimenez W, Welch S, et al.
Nat Commun
. 2023 Mar;
14(1):1452.
PMID: 36922497
This multi-centre, non-randomized, open-label, phase II trial (NCT03016338), assessed niraparib monotherapy (cohort 1, C1), or niraparib and dostarlimab (cohort 2, C2) in patients with recurrent serous or endometrioid endometrial carcinoma....
10.
Marastoni S, Madariaga A, Pesic A, Nair S, Li Z, Shalev Z, et al.
Cancer Res Commun
. 2023 Mar;
2(5):293-306.
PMID: 36875717
Significance: The combination of the antifungal drug itraconazole with antimalarial drug hydroxychloroquine leads to a cytotoxic lysosomal dysfunction, supporting the rational for further research on lysosomal targeting in ovarian cancer.